Indivior to Delist from London Stock Exchange, Sharpens Focus on U.S. Market
By
Fiona Craig
PUBLISHED:
02 Jun 2025 @ 18:16
|
Comments (0)
|
More info about Fiona Craig
© © NIH Lab Research
Indivior PLC (LSE:INDV) has announced plans to cancel its secondary listing on the London Stock Exchange, choosing to maintain its primary listing on Nasdaq. The decision is part of a broader strategy to concentrate on the U.S. market, which accounts for more than 80% of the company’s net revenue.
By ending its UK listing, Indivior aims to reduce operational complexity and associated costs. The company cited stronger trading volumes and a larger shareholder base in the U.S. as key factors in the move. The delisting is expected to streamline operations and bring Indivior into closer alignment with its U.S.-based pharmaceutical peers.
More about Indivior
Indivior is a global pharmaceutical company dedicated to developing treatments for opioid use disorder (OUD). With a mission to transform OUD from a crisis into a treatable chronic condition, the company offers a range of evidence-based therapies. Headquartered in Richmond, Virginia, Indivior employs more than 1,000 people worldwide and remains a leading voice in addressing addiction through medical innovation.
CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).
This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.
Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
